These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29452300)

  • 21. Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis.
    Cavalli G; Favalli EG
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1313-1322. PubMed ID: 31663390
    [No Abstract]   [Full Text] [Related]  

  • 22. Is it possible to withdraw biologics from therapy in rheumatoid arthritis?
    Tanaka Y; Hirata S
    Clin Ther; 2013 Dec; 35(12):2028-35. PubMed ID: 24290736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity.
    Ye W; Tucker LJ; Coates LC
    Drugs; 2018 Nov; 78(16):1705-1715. PubMed ID: 30341684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
    Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
    Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
    Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA
    Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial).
    Uhrenholt L; Schlemmer A; Hauge EM; Christensen R; Dreyer L; Suarez-Almazor ME; Kristensen S
    BMJ Open; 2019 Jul; 9(7):e028517. PubMed ID: 31292181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
    An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
    Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of down-titration versus continuation strategies of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis with low disease activity or in remission: a systematic review and meta-analysis.
    Jiang M; Ren F; Zheng Y; Yan R; Huang W; Xia N; Luo L; Zhou J; Tang L
    Clin Exp Rheumatol; 2017; 35(1):152-160. PubMed ID: 27749238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis.
    Besselink NJ; Westgeest AAA; Klaasen R; Gamala M; van Woerkom JM; Tekstra J; Verhoeven MMA; Van Spil WE; Lafeber FPJG; Marijnissen ACA; Van Laar JM; Jacobs JWG
    Trials; 2019 Apr; 20(1):226. PubMed ID: 30999969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission.
    El Miedany Y; El Gaafary M; Youssef S; Ahmed I; Bahlas S; Hegazi M; Nasr A
    Clin Rheumatol; 2016 Dec; 35(12):2915-2923. PubMed ID: 27658417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial.
    Messelink MA; van der Leeuw MS; den Broeder AA; Tekstra J; van der Goes MC; Heijstek MW; Lafeber F; Welsing PMJ
    Trials; 2022 Jun; 23(1):494. PubMed ID: 35710576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological disease-modifying antirheumatic drugs.
    Valor L; Garrido J; Martínez-Estupiñán L; Hernández-Flórez D; Janta I; López-Longo FJ; Monteagudo I; González CM; Naredo E
    Rheumatol Int; 2018 Aug; 38(8):1465-1470. PubMed ID: 29915991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
    Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
    Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current concepts in the management of rheumatoid arthritis.
    Tanaka Y
    Korean J Intern Med; 2016 Mar; 31(2):210-8. PubMed ID: 26932398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission.
    Jurgens MS; Welsing PM; Jacobs JW
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S56-63. PubMed ID: 23078808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability.
    Verstappen M; van Mulligen E; de Jong PHP; van der Helm-Van Mil AHM
    RMD Open; 2020 May; 6(1):. PubMed ID: 32393523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.
    Emery P; Burmester GR; Naredo E; Sinigaglia L; Lagunes I; Koenigsbauer F; Conaghan PG
    Ann Rheum Dis; 2020 Aug; 79(8):1023-1030. PubMed ID: 32404343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment algorithm for rheumatoid arthritis : According to the S2e guidelines 2018].
    Fiehn C; Krüger K
    Z Rheumatol; 2019 Aug; 78(6):529-539. PubMed ID: 31297605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study.
    Tanaka Y; Yamaguchi A; Miyamoto T; Tanimura K; Iwai H; Kaneko Y; Takeuchi T; Amano K; Iwamoto N; Kawakami A; Murakami M; Nishimoto N; Atsumi T; Sumida T; Ohmura K; Mimori T; Yamanaka H; Fujio K; Fujino Y; Saito K; Nakano K; Hirata S; Nakayamada S
    Rheumatology (Oxford); 2022 Nov; 61(11):4273-4285. PubMed ID: 35136990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?
    Atzeni F; Benucci M; Talotta R; Masala IF; Sarzi-Puttini P; Govoni M
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1403-1411. PubMed ID: 27634311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.